<DOC>
	<DOCNO>NCT02977364</DOCNO>
	<brief_summary>To investigate safety , tolerability pharmacokinetics C-met Kinase Inhibitor HS-10241 Subjects With Advanced Solid Tumours eligible conventional intensive treatment . The dose HS-10241 escalate determine dose limit toxicity ( DLT ) maximum tolerate dose ( MTD ) HS-10241 advanced cancer patient . At time , pharmacokinetic characteristic preliminary efficacy HS-10241 observe advanced cancer patient . To determine recommended dosage regimen phase II .</brief_summary>
	<brief_title>A Trial C-met Kinase Inhibitor HS-10241 Subjects With Advanced Solid Tumours</brief_title>
	<detailed_description />
	<criteria>1 . Histologically confirm advanced metastatic solid tumor standard therapy exist , fail , refuse . 2. cMET positive patient prefer dose escalation phase ; cMET patient must fulfill ICH++~+++ FISH≥4 time dose expansion phase . 3 . Confirmed least 1 measure accordance standard RECIST1.1 CT MRI . 4 . 18 ~65 year age . 5 . ECOG performance status 0~1 . 6 . Life expectancy least 3 month . 7 . Recovered toxicity prior anticancer treatment Grade 1 less ( except alopecia ) . 8 . Acceptable hematologic status ( without hematologic support include hematopoietic factor , blood transfusion ) define : Absolute neutrophil count ( ANC ) ≥ 1500/μL Platelet count ≥ 100000/μL Hemoglobin ≥ 9.0 g/dL 9 . Acceptable liver function define : Total bilirubin ≤ 2 time upper limit normal range ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 3 time ULN ; however , ≤ 5 time ULN subject liver metastases 10 . Acceptable renal function define : Serum creatinine ≤ 1.5 time ULN calculate creatinine clearance ( CockcroftGault formula ) ≥ 60 mL/minutes 11 . Acceptable coagulation status define : Prothrombin time &lt; 1.5 time ULN Partial thrombin time &lt; 1.5 time UL 12 . HIV Ag/Ab ( ) . 13 . HCV Ab ( ) ; HCV Ab ( + ) HCV RNA ( ) . 14 . HBsAg（）and HBcAb（）in dose escalation phase；HBV DNA &lt; 1×103copies/ml HBsAg（+）or HBcAb（+）in dose expansion phase . 15 . Ability understand purpose risk trial his/her inform consent use human research ethic committee ( HREC ) approve informed consent form obtain enter trial . 1 . Treatment cMET TKI ( specific target multitarget ) ； 2 . Anticancer treatment radiation therapy（not include non target lesion receive palliative radiotherapy） , chemotherapy , hormonotherapy surgery（small surgery , include implantation external equipment fine needle aspiration , least 7 day ; diagnostic palliative surgery , least 14 days） within 4 week ( 6 week nitrosoureas Mitomycin C ) prior trial entry . 3 . Medical history difficulty swallowing , malabsorption chronic gastrointestinal disease , condition may hamper compliance and/or absorption test product 4 . Cardiac disease New York Heart Association ( NYHA ) Class III IV , include congestive heart failure , myocardial infarction within 6 month prior trial entry , unstable arrhythmia , symptomatic peripheral arterial vascular disease . 5 . Symptomatic brain metastasis unstable brain metastasis ( note : Patients asymptomatic brain metastasis previously treat study , must keep stable least 4 week receive stable dose drug ) 6 . Obvious neurological mental disorder . 7 . Other previous concomitant tumor ( except effective treatment melanoma , cervical carcinoma situ , ductal carcinoma situ malignant tumor effective treatment , remission 3 year consider cure ) . 8 . Active , uncontrolled bacterial , fungal infection , require systemic therapy . 9 . Recent venous thrombosis ( include deep vein thrombosis pulmonary embolism within 0.5 year trial entry ) 10 . History organ allograft , autologous stem cell transplantation , allogeneic stem cell transplantation . 11 . Participation investigational drug device trial within 4 week prior trial entry . 12 . Anticancer treatment radiation therapy , chemotherapy immunotherapy within 4 week ( 6 week nitrosoureas Mitomycin C ) prior trial entry . 13 . Major surgery , diagnostic surgery , within 4 week prior trial entry , without complete recovery 14 . Taking medication moderate strong inhibitor inducer CYP2C9 ; take medication prolongs QT interval risk Torsades de Pointes . 15 . Pregnant ( positive serum beta human chorionic gonadotropin [ βHCG ] test Screening ) currently breastfeed , partner anticipates become pregnant/impregnating trial within 6 month receive last dose trial treatment . 16 . Known drug abuse alcohol abuse . 17 . Concomitant disease condition could interfere conduct trial , would , opinion Investigator , pose unacceptable risk subject trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>